Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Gastric Adenocarcinoma 2Advanced Gastric Cancer 2Thymic epithelial tumor 1Solid Tumor 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neuroendocrine Tumors 1Locally Advanced Gastric Cancer 1Liver Neoplasms 1Liposarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 21130-nm albumin-bound paclitaxel 8irinotecan sucrosofate 7Oxaliplatin 7Leucovorin 7Fluorouracil 7Taxes 5Drug Therapy 5Albumin-Bound Paclitaxel 4toripalimab 3Specimen Handling 3S 1 (combination) 3Paclitaxel 3Irinotecan 3Injections 3zimberelimab 2surufatinib 2camrelizumab 2Pemetrexed 2Pancreaticoduodenectomy 2Magnetic Resonance Spectroscopy 2Exercise 2Capecitabine 2Blood Specimen Collection 2Biopsy 2trastuzumab deruxtecan 1sintilimab 1semaglutide 1potassium oxonate 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Pancreatic Neoplasms × apatinib × Clear all
NCT06759090 2025-01-06

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Zhejiang University

Phase 2 Not yet recruiting
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡